IMGN News and Press, ImmunoGen Inc. From 02/24/21

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...

ImmunoGen, Inc. (IMGN) Q4 2020 Earnings Conference Call February 12, 2021 08:00 ET Company Participants Courtney O’Konek - Senior Director, Corporate Communications and Investor Relations Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Chief Medical Officer Susan ...

Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...

Gainers: Artelo Biosciences (ARTL) +82%.Wunong Net Technology Company (WNW) +72%.China Liberal Education Holdings (CLEU) +53%.ION Geophysical (IO) +42%.Top Ships (TOPS) +42%.Seanergy Maritime Holdings (SHIP) +34%.Luokung Technology (LKCO) +29%.ImmunoGen (IMGN) +29%.EuroDry (EDRY) +28%.Lizhi (...

Image source: The Motley Fool. Immunogen Inc (NASDAQ: IMGN) Q4 2020 Earnings Call Feb 12, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Immunogen Inc (IMGN) Q4 2020 Earnings Call Transcript

If you liked the gains generated by ImmunoGen (NASDAQ: IMGN) in 2020, you're loving the stock in 2021. So far this year, the biotech's shares have soared 32%. And that momentum is now likely to build even more. ImmunoGen announced its fourth-quarter results before the market ope...

ImmunoGen (IMGN) Q4 results:Revenues: $85.8M (+91.3%), beats by $44.97M; non-cash royalty revenue: $23.4M, compared with $15.3M last year, helped by rising global sales of breast cancer treatment Kadcyla; Research and development expenses were $39.6M vs $26.1M.Net inc...

ImmunoGen (IMGN): Q4 GAAP EPS of $0.16 beats by $0.24.Revenue of $85.8M (+91.3% Y/Y) beats by $44.97M.For 2021, ImmunoGen expects: Revenues between $65M and $75M; operating expenses between $200M and $210M; and cash and cash equivalents at December 31, 2021 to be between $140M and $150M....

Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Fund...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...